Neuland LaboratoriesNSE:NEULANDLAB -0.18%90 5-Year Yield-on-Cost % is 0.46 as of Jul. 11, 2026, which is 67% below its 10-year median of 1.39. GuruFocus rates NSE:NEULANDLAB with a GF Score™ of 90/100 and a GF Value™ of ₹16,036.83 (Modestly Overvalued). The stock has 3 warning signs investors should review. Among 516 Drug Manufacturers companies, Neuland Laboratories ranks worse than 84.5% on this metric.
Neuland Laboratories's yield on cost for the quarter that ended in Mar. 2026 was 0.46.
The historical rank and industry rank for Neuland Laboratories's 5-Year Yield-on-Cost % or its related term are showing as below:
NSE:NEULANDLAB'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.46 Med: 1.39 Max: 8.7
Current: 0.46
During the past 13 years, Neuland Laboratories's highest Yield on Cost was 8.70. The lowest was 0.46. And the median was 1.39.
NSE:NEULANDLAB's 5-Year Yield-on-Cost % is ranked worse than 84.5% of 516
companies
in the Drug Manufacturers industry
Industry Median: 2.24
vs NSE:NEULANDLAB: 0.46
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Neuland Laboratories 5-Year Yield-on-Cost % Related Terms
NSE:NEULANDLAB vs ZTS, UTHR: 5-Year Yield-on-Cost % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Neuland Laboratories's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Neuland Laboratories 5-Year Yield-on-Cost % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Neuland Laboratories's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Neuland Laboratories's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Neuland Laboratories (NSE:NEULANDLAB) has a 5-Year Yield-on-Cost % of 0.46 as of Jul. 11, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Neuland Laboratories and its competitors. This is 67% below median its historical median of 1.39. Over the past decade, Neuland Laboratories' 5-Year Yield-on-Cost % has ranged from 0.46 to 8.70. According to the industry distribution chart, Neuland Laboratories ranks #436 out of 516 companies in the Drug Manufacturers industry, placing it in the top 84.5%.
Is Neuland Laboratories' 5-Year Yield-on-Cost % too high?
Neuland Laboratories' current 5-Year Yield-on-Cost % of 0.46 is 67% below median its 10-year median of 1.39. Over the past 10 years, this metric has ranged from a low of 0.46 to a high of 8.70. The Drug Manufacturers industry median 5-Year Yield-on-Cost % is 2.24. Neuland Laboratories' value of 0.46 is 79.5% below this industry median. Based on the distribution chart, Neuland Laboratories ranks #436 out of 516 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Neuland Laboratories has a GF Score™ of 90/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Neuland Laboratories' 5-Year Yield-on-Cost % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Neuland Laboratories ranks #436 out of 516 companies for 5-Year Yield-on-Cost %. This places Neuland Laboratories in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.24. Neuland Laboratories' value of 0.46 is 79.5% below this benchmark. Historically, Neuland Laboratories' own 5-Year Yield-on-Cost % has ranged from 0.46 to 8.70 over the past decade. While the company's 10-year median is 1.39 vs. the industry median of 2.24, Neuland Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Drug Manufacturers company?
The median 5-Year Yield-on-Cost % among Drug Manufacturers companies is 2.24, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Neuland Laboratories's current 5-Year Yield-on-Cost % of 0.46 is 79.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Neuland Laboratories and its competitors. For the Drug Manufacturers industry, the median 5-Year Yield-on-Cost % is 2.24 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Neuland Laboratories's current 5-Year Yield-on-Cost % is 0.46, which is 67% below median its own 10-year median of 1.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Neuland Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Neuland Laboratories (NSE:NEULANDLAB) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹16,036.83, compared to a current price of ₹19,506.00 — trading 21.6% above its estimated fair value. The current 5-Year Yield-on-Cost % is 0.46, which is 67% below median its 10-year median of 1.39 and 79.5% below the Drug Manufacturers industry median of 2.24. Neuland Laboratories' overall GF Score™ is 90/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Neuland Laboratories (NSE:NEULANDLAB), the current 5-Year Yield-on-Cost % is 0.46 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Neuland Laboratories (NSE:NEULANDLAB) Overvalued in 2026?
Based on GuruFocus' analysis, Neuland Laboratories stock appears to be overvalued.
The current stock price of ₹19,506.00 is trading 21.6% above its estimated GF Value™ of ₹16,036.83.
GuruFocus considers Neuland Laboratories to be Modestly Overvalued.
Key valuation signals for NSE:NEULANDLAB:
5-Year Yield-on-Cost %: 0.46 (67% below median its 10-year median of 1.39)
GF Value™: ₹16,036.83 vs. price of ₹19,506.00 (21.6% above fair value)
Industry Position: 79.5% below the Drug Manufacturers median (#436 of 516)
No single metric tells the full story. See the NSE:NEULANDLAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Neuland Laboratories Ltd is engaged in the manufacturing and selling of bulk drugs and caters to both the domestic and international markets. It is an API contract development and manufacturing organization (CDMO), supporting biotechnology and pharmaceutical companies in the design, development, and manufacturing of complex active pharmaceutical ingredients (APIs). The company develops small molecules and peptides for clinical trials and beyond, with the capacity to scale up through every stage of the product lifecycle to commercial manufacturing. Geographically, the group derives maximum revenue from its customers in India, followed by Europe, the USA and North America, and the Rest of the world.
90GF Score
Get the complete analysis for NSE:NEULANDLAB
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NEULANDLAB has been successfully added to your 